Skip to content

Vertex Pharmaceuticals

NASDAQ: VRTX · USD

Vertex Pharmaceuticals financials

6 charts

Revenue

USD millions

$3,333.9M
Vertex Pharmaceuticals Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2010 Q1$22.429M; Change unavailable vs FY 2009 Q4
FY 2010 Q2$31.622M; +41.0% vs FY 2010 Q1
FY 2010 Q3$23.795M; −24.8% vs FY 2010 Q2
FY 2010 Q4$65.524M; +175.4% vs FY 2010 Q3
FY 2011 Q1$73.662M; +12.4% vs FY 2010 Q4
FY 2011 Q2$114.424M; +55.3% vs FY 2011 Q1
FY 2011 Q3$659.2M; +476.1% vs FY 2011 Q2
FY 2011 Q4$563.34M; −14.5% vs FY 2011 Q3
FY 2012 Q1$438.737M; −22.1% vs FY 2011 Q4
FY 2012 Q2$418.305M; −4.7% vs FY 2012 Q1
FY 2012 Q3$336.006M; −19.7% vs FY 2012 Q2
FY 2012 Q4$333.994M; −0.6% vs FY 2012 Q3
FY 2013 Q1$328.368M; −1.7% vs FY 2012 Q4
FY 2013 Q2$310.75M; −5.4% vs FY 2013 Q1
FY 2013 Q3$221.7M; −28.7% vs FY 2013 Q2
FY 2013 Q4$351.157M; +58.4% vs FY 2013 Q3
FY 2014 Q1$118.451M; −66.3% vs FY 2013 Q4
FY 2014 Q2$138.421M; +16.9% vs FY 2014 Q1
FY 2014 Q3$178.987M; +29.3% vs FY 2014 Q2
FY 2014 Q4$144.556M; −19.2% vs FY 2014 Q3
FY 2015 Q1$138.509M; −4.2% vs FY 2014 Q4
FY 2015 Q2$166.076M; +19.9% vs FY 2015 Q1
FY 2015 Q3$309.816M; +86.6% vs FY 2015 Q2
FY 2015 Q4$417.935M; +34.9% vs FY 2015 Q3
FY 2016 Q1$398.08M; −4.8% vs FY 2015 Q4
FY 2016 Q2$431.608M; +8.4% vs FY 2016 Q1
FY 2016 Q3$413.783M; −4.1% vs FY 2016 Q2
FY 2016 Q4$458.706M; +10.9% vs FY 2016 Q3
FY 2017 Q1$714.718M; +55.8% vs FY 2016 Q4
FY 2017 Q2$544.135M; −23.9% vs FY 2017 Q1
FY 2017 Q3$578.165M; +6.3% vs FY 2017 Q2
FY 2017 Q4$651.634M; +12.7% vs FY 2017 Q3
FY 2018 Q1$640.799M; −1.7% vs FY 2017 Q4
FY 2018 Q2$752.157M; +17.4% vs FY 2018 Q1
FY 2018 Q3$784.535M; +4.3% vs FY 2018 Q2
FY 2018 Q4$870.106M; +10.9% vs FY 2018 Q3
FY 2019 Q1$858.435M; −1.3% vs FY 2018 Q4
FY 2019 Q2$941.293M; +9.7% vs FY 2019 Q1
FY 2019 Q3$949.828M; +0.9% vs FY 2019 Q2
FY 2019 Q4$1,413.265M; +48.8% vs FY 2019 Q3
FY 2020 Q1$1,515.107M; +7.2% vs FY 2019 Q4
FY 2020 Q2$1,524.485M; +0.6% vs FY 2020 Q1
FY 2020 Q3$1,538.271M; +0.9% vs FY 2020 Q2
FY 2020 Q4$1,627.82M; +5.8% vs FY 2020 Q3
FY 2021 Q1$1,724.305M; +5.9% vs FY 2020 Q4
FY 2021 Q2$1,793.37M; +4.0% vs FY 2021 Q1
FY 2021 Q3$1,984.164M; +10.6% vs FY 2021 Q2
FY 2021 Q4$2,072.561M; +4.5% vs FY 2021 Q3
FY 2022 Q1$2,097.5M; +1.2% vs FY 2021 Q4
FY 2022 Q2$2,196.2M; +4.7% vs FY 2022 Q1
FY 2022 Q3$2,334.3M; +6.3% vs FY 2022 Q2
FY 2022 Q4$2,302.7M; −1.4% vs FY 2022 Q3
FY 2023 Q1$2,374.8M; +3.1% vs FY 2022 Q4
FY 2023 Q2$2,493.2M; +5.0% vs FY 2023 Q1
FY 2023 Q3$2,483.5M; −0.4% vs FY 2023 Q2
FY 2023 Q4$2,517.7M; +1.4% vs FY 2023 Q3
FY 2024 Q1$2,690.6M; +6.9% vs FY 2023 Q4
FY 2024 Q2$2,645.6M; −1.7% vs FY 2024 Q1
FY 2024 Q3$2,771.9M; +4.8% vs FY 2024 Q2
FY 2024 Q4$2,912M; +5.1% vs FY 2024 Q3
FY 2025 Q1$2,770.2M; −4.9% vs FY 2024 Q4
FY 2025 Q2$2,964.7M; +7.0% vs FY 2025 Q1
FY 2025 Q3$3,076.4M; +3.8% vs FY 2025 Q2
FY 2025 Q4$3,190M; +3.7% vs FY 2025 Q3
FY 2026 Q1$2,986.9M; −6.4% vs FY 2025 Q4
FY 2026 Q2$3,333.9M; +11.6% vs FY 2026 Q1
Mar 31, 2010 through Sep 25, 2026

Free cash flow

USD millions

$1,013.2M
Vertex Pharmaceuticals Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2010 Q1$-199.572M; Change unavailable vs FY 2009 Q4
FY 2010 Q2$-118.573M; +40.6% vs FY 2010 Q1
FY 2010 Q3$-174.82M; −47.4% vs FY 2010 Q2
FY 2010 Q4$-180.531M; −3.3% vs FY 2010 Q3
FY 2011 Q1$-191.478M; −6.1% vs FY 2010 Q4
FY 2011 Q2$-226.626M; −18.4% vs FY 2011 Q1
FY 2011 Q3$32.91M; +114.5% vs FY 2011 Q2
FY 2011 Q4$494.334M; +1402.1% vs FY 2011 Q3
FY 2012 Q1$-3.239M; −100.7% vs FY 2011 Q4
FY 2012 Q2$102.862M; +3275.7% vs FY 2012 Q1
FY 2012 Q3$84.565M; −17.8% vs FY 2012 Q2
FY 2012 Q4$12.513M; −85.2% vs FY 2012 Q3
FY 2013 Q1$-82.385M; −758.4% vs FY 2012 Q4
FY 2013 Q2$-2.728M; +96.7% vs FY 2013 Q1
FY 2013 Q3$-32.234M; −1081.6% vs FY 2013 Q2
FY 2013 Q4$14.384M; +144.6% vs FY 2013 Q3
FY 2014 Q1$-191.288M; −1429.9% vs FY 2013 Q4
FY 2014 Q2$-139.621M; +27.0% vs FY 2014 Q1
FY 2014 Q3$-96.945M; +30.6% vs FY 2014 Q2
FY 2014 Q4$-136.546M; −40.8% vs FY 2014 Q3
FY 2015 Q1$-217.739M; −59.5% vs FY 2014 Q4
FY 2015 Q2$-108.633M; +50.1% vs FY 2015 Q1
FY 2015 Q3$-55.821M; +48.6% vs FY 2015 Q2
FY 2015 Q4$-28.541M; +48.9% vs FY 2015 Q3
FY 2016 Q1$-27.111M; +5.0% vs FY 2015 Q4
FY 2016 Q2$24.942M; +192.0% vs FY 2016 Q1
FY 2016 Q3$51.773M; +107.6% vs FY 2016 Q2
FY 2016 Q4$129.936M; +151.0% vs FY 2016 Q3
FY 2017 Q1$254.533M; +95.9% vs FY 2016 Q4
FY 2017 Q2$163.946M; −35.6% vs FY 2017 Q1
FY 2017 Q3$142.135M; −13.3% vs FY 2017 Q2
FY 2017 Q4$184.907M; +30.1% vs FY 2017 Q3
FY 2018 Q1$223.378M; +20.8% vs FY 2017 Q4
FY 2018 Q2$292.091M; +30.8% vs FY 2018 Q1
FY 2018 Q3$360.436M; +23.4% vs FY 2018 Q2
FY 2018 Q4$298.857M; −17.1% vs FY 2018 Q3
FY 2019 Q1$306.743M; +2.6% vs FY 2018 Q4
FY 2019 Q2$447.391M; +45.9% vs FY 2019 Q1
FY 2019 Q3$310.498M; −30.6% vs FY 2019 Q2
FY 2019 Q4$429.247M; +38.2% vs FY 2019 Q3
FY 2020 Q1$796.248M; +85.5% vs FY 2019 Q4
FY 2020 Q2$1,020.663M; +28.2% vs FY 2020 Q1
FY 2020 Q3$732.953M; −28.2% vs FY 2020 Q2
FY 2020 Q4$443.843M; −39.4% vs FY 2020 Q3
FY 2021 Q1$850.129M; +91.5% vs FY 2020 Q4
FY 2021 Q2$-249.604M; −129.4% vs FY 2021 Q1
FY 2021 Q3$874.697M; +450.4% vs FY 2021 Q2
FY 2021 Q4$933.278M; +6.7% vs FY 2021 Q3
FY 2022 Q1$892.6M; −4.4% vs FY 2021 Q4
FY 2022 Q2$1,086.5M; +21.7% vs FY 2022 Q1
FY 2022 Q3$901.3M; −17.0% vs FY 2022 Q2
FY 2022 Q4$1,044.8M; +15.9% vs FY 2022 Q3
FY 2023 Q1$857.8M; −17.9% vs FY 2022 Q4
FY 2023 Q2$1,074.8M; +25.3% vs FY 2023 Q1
FY 2023 Q3$1,227.8M; +14.2% vs FY 2023 Q2
FY 2023 Q4$176.5M; −85.6% vs FY 2023 Q3
FY 2024 Q1$1,238.2M; +601.5% vs FY 2023 Q4
FY 2024 Q2$-3,822.6M; −408.7% vs FY 2024 Q1
FY 2024 Q3$1,302.1M; +134.1% vs FY 2024 Q2
FY 2024 Q4$492M; −62.2% vs FY 2024 Q3
FY 2025 Q1$778.2M; +58.2% vs FY 2024 Q4
FY 2025 Q2$927.4M; +19.2% vs FY 2025 Q1
FY 2025 Q3$1,139.6M; +22.9% vs FY 2025 Q2
FY 2025 Q4$348.6M; −69.4% vs FY 2025 Q3
FY 2026 Q1$1,294.7M; +271.4% vs FY 2025 Q4
FY 2026 Q2$1,013.2M; −21.7% vs FY 2026 Q1

Net margin

%

32.99%
Vertex Pharmaceuticals Net margin. Reported fiscal history.
Fiscal period%
FY 2010 Q1-736.86%
FY 2010 Q2-632.49%
FY 2010 Q3-878.16%
FY 2010 Q4-275.31%
FY 2011 Q1-239.06%
FY 2011 Q2-152.13%
FY 2011 Q333.54%
FY 2011 Q428.16%
FY 2012 Q120.88%
FY 2012 Q2-15.52%
FY 2012 Q3-17.13%
FY 2012 Q4-22.8%
FY 2013 Q1-93.8%
FY 2013 Q2-18.4%
FY 2013 Q3-55.99%
FY 2013 Q412.61%
FY 2014 Q1-196.25%
FY 2014 Q2-115.14%
FY 2014 Q3-95.01%
FY 2014 Q4-122.21%
FY 2015 Q1-143.39%
FY 2015 Q2-113.71%
FY 2015 Q3-30.71%
FY 2015 Q4-17.64%
FY 2016 Q1-10.46%
FY 2016 Q2-14.95%
FY 2016 Q3-9.39%
FY 2016 Q47.18%
FY 2017 Q134.66%
FY 2017 Q23.31%
FY 2017 Q3-17.81%
FY 2017 Q415.45%
FY 2018 Q132.81%
FY 2018 Q227.57%
FY 2018 Q316.41%
FY 2018 Q4178.2%
FY 2019 Q131.29%
FY 2019 Q228.41%
FY 2019 Q36.06%
FY 2019 Q441.27%
FY 2020 Q139.78%
FY 2020 Q254.92%
FY 2020 Q343.39%
FY 2020 Q437.12%
FY 2021 Q137.88%
FY 2021 Q23.73%
FY 2021 Q342.94%
FY 2021 Q437.16%
FY 2022 Q136.33%
FY 2022 Q236.9%
FY 2022 Q339.86%
FY 2022 Q435.56%
FY 2023 Q129.47%
FY 2023 Q236.73%
FY 2023 Q341.69%
FY 2023 Q438.48%
FY 2024 Q140.87%
FY 2024 Q2-135.83%
FY 2024 Q337.71%
FY 2024 Q431.35%
FY 2025 Q123.33%
FY 2025 Q234.84%
FY 2025 Q335.2%
FY 2025 Q437.34%
FY 2026 Q134.53%
FY 2026 Q232.99%

P/E

× · TTM · Daily

30.48×
Vertex Pharmaceuticals P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-29289.21×2011-12-31
2012-03-30304.75×2011-12-31
2012-04-30285.94×2011-12-31
2012-05-31446.16×2011-12-31
2012-06-29415.54×2011-12-31
2012-07-31360.48×2011-12-31
2012-08-3127.94×2012-06-30
2012-09-2829.28×2012-06-30
2012-10-3125.3×2012-06-30
2012-11-3067.06×2012-09-30
2012-12-3170.62×2012-09-30
2013-01-3175.47×2012-09-30
2013-02-2878.91×2012-09-30
2013-03-28—2012-12-31
2013-04-30—2012-12-31
2013-05-31—2012-12-31
2013-06-28—2012-12-31
2013-07-31—2012-12-31
2013-08-30—2012-12-31
2013-09-30—2012-12-31
2013-10-31—2012-12-31
2013-11-29—2013-09-30
2013-12-31—2013-09-30
2014-01-31—2013-09-30
2014-02-28—2013-12-31
2014-03-31—2013-12-31
2014-04-30—2013-12-31
2014-05-30—2014-03-31
2014-06-30—2014-03-31
2014-07-31—2014-03-31
2014-08-29—2014-06-30
2014-09-30—2014-06-30
2014-10-31—2014-06-30
2014-11-28—2014-09-30
2014-12-31—2014-09-30
2015-01-30—2014-09-30
2015-02-27—2014-12-31
2015-03-31—2014-12-31
2015-04-30—2014-12-31
2015-05-29—2015-03-31
2015-06-30—2015-03-31
2015-07-31—2015-03-31
2015-08-31—2015-06-30
2015-09-30—2015-06-30
2015-10-30—2015-06-30
2015-11-30—2015-09-30
2015-12-31—2015-09-30
2016-01-29—2015-09-30
2016-02-29—2015-12-31
2016-03-31—2015-12-31
2016-04-29—2015-12-31
2016-05-31—2016-03-31
2016-06-30—2016-03-31
2016-07-29—2016-03-31
2016-08-31—2016-06-30
2016-09-30—2016-06-30
2016-10-31—2016-06-30
2016-11-30—2016-09-30
2016-12-30—2016-09-30
2017-01-31—2016-09-30
2017-02-28—2016-12-31
2017-03-31—2016-12-31
2017-04-28—2016-12-31
2017-05-31173.74×2017-03-31
2017-06-30181.15×2017-03-31
2017-07-31147.26×2017-06-30
2017-08-31155.72×2017-06-30
2017-09-29147.47×2017-06-30
2017-10-31187.37×2017-09-30
2017-11-30184.89×2017-09-30
2017-12-29192.02×2017-09-30
2018-01-31213.82×2017-09-30
2018-02-28162×2017-12-31
2018-03-29159.02×2017-12-31
2018-04-30175.3×2018-03-31
2018-05-31176.27×2018-03-31
2018-06-29194.53×2018-03-31
2018-07-31109.02×2018-06-30
2018-08-31114.85×2018-06-30
2018-09-28120.04×2018-06-30
2018-10-3168.06×2018-09-30
2018-11-3072.61×2018-09-30
2018-12-3166.55×2018-09-30
2019-01-3176.67×2018-09-30
2019-02-2823.39×2018-12-31
2019-03-2922.8×2018-12-31
2019-04-3020.94×2018-12-31
2019-05-3120.06×2019-03-31
2019-06-2822.14×2019-03-31
2019-07-3120.11×2019-03-31
2019-08-3021.73×2019-03-31
2019-09-3020.45×2019-03-31
2019-10-3123.6×2019-03-31
2019-11-2926.77×2019-03-31
2019-12-3126.43×2019-03-31
2020-01-3127.41×2019-03-31
2020-02-2827.05×2019-03-31
2020-03-3128.73×2019-03-31
2020-04-3030.32×2019-03-31
2020-05-2934.76×2019-03-31
2020-06-3035.05×2019-03-31
2020-07-3132.84×2019-03-31
2020-08-3133.7×2019-03-31
2020-09-3032.85×2019-03-31
2020-10-3025.15×2019-03-31
2020-11-3022.35×2020-09-30
2020-12-3123.2×2020-09-30
2021-01-2922.48×2020-09-30
2021-02-2620.86×2020-09-30
2021-03-3121.09×2020-09-30
2021-04-3021.42×2020-09-30
2021-05-2819.78×2021-03-31
2021-06-3019.12×2021-03-31
2021-07-3019.12×2021-03-31
2021-08-3126.25×2021-06-30
2021-09-3023.77×2021-06-30
2021-10-2924.24×2021-06-30
2021-11-3022.31×2021-09-30
2021-12-3126.21×2021-09-30
2022-01-3129.01×2021-09-30
2022-02-2825.24×2021-12-31
2022-03-3128.64×2021-12-31
2022-04-2929.98×2021-12-31
2022-05-3128.27×2022-03-31
2022-06-3029.65×2022-03-31
2022-07-2929.5×2022-03-31
2022-08-3122.82×2022-06-30
2022-09-3023.45×2022-06-30
2022-10-3124.74×2022-09-30
2022-11-3025.08×2022-09-30
2022-12-3022.89×2022-09-30
2023-01-3125.62×2022-09-30
2023-02-2822.74×2022-12-31
2023-03-3124.69×2022-12-31
2023-04-2826.7×2022-12-31
2023-05-3125.84×2023-03-31
2023-06-3028.1×2023-03-31
2023-07-3128.14×2023-03-31
2023-08-3126.96×2023-06-30
2023-09-2926.91×2023-06-30
2023-10-3128.02×2023-06-30
2023-11-3026.65×2023-09-30
2023-12-2930.56×2023-09-30
2024-01-3132.55×2023-09-30
2024-02-2930.31×2023-12-31
2024-03-2830.12×2023-12-31
2024-04-3028.3×2023-12-31
2024-05-3129.58×2024-03-31
2024-06-2830.45×2024-03-31
2024-07-3132.2×2024-03-31
2024-08-3032.21×2024-03-31
2024-09-3030.21×2024-03-31
2024-10-3130.92×2024-03-31
2024-11-2930.41×2024-03-31
2024-12-3126.16×2024-03-31
2025-01-3129.99×2024-03-31
2025-02-28—2024-12-31
2025-03-31—2024-12-31
2025-04-30—2024-12-31
2025-05-30—2024-12-31
2025-06-30—2024-12-31
2025-07-31—2024-12-31
2025-08-29—2024-12-31
2025-09-30—2024-12-31
2025-10-31—2024-12-31
2025-11-2830.39×2025-09-30
2025-12-3131.78×2025-09-30
2026-01-3032.94×2025-09-30
2026-02-2732.2×2025-12-31
2026-03-3128.94×2025-12-31
2026-04-3027.7×2025-12-31
2026-05-2926.44×2026-03-31
2026-06-3029.35×2026-03-31
2026-07-3128.19×2026-03-31
2026-08-3131.54×2026-06-30
2026-09-2530.48×2026-06-30
Mean 67.04×Median 29.28×4% above median

ROIC

% · Annual / TTM

—
Reported borrowing balances are unavailable in the extracted statements for this period.
Vertex Pharmaceuticals ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$581.7M
Vertex Pharmaceuticals capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q1100% · $3.11MUnavailableUnavailableUnavailableUnavailable100% · $3.11M
FY 2010 Q2100% · $9.686MUnavailableUnavailableUnavailableUnavailable100% · $9.686M
FY 2010 Q3100% · $10.83MUnavailableUnavailableUnavailableUnavailable100% · $10.83M
FY 2010 Q4100% · $14.428MUnavailableUnavailableUnavailableUnavailable100% · $14.428M
FY 2011 Q18.84% · $4.85MUnavailableUnavailableUnavailable91.16% · $50M100% · $54.85M
FY 2011 Q2100% · $10.431MUnavailableUnavailableUnavailable0% · $0M100% · $10.431M
FY 2011 Q3100% · $9.985MUnavailableUnavailableUnavailable0% · $0M100% · $9.985M
FY 2011 Q48.16% · $9.329MUnavailableUnavailableUnavailable91.84% · $105M100% · $114.329M
FY 2012 Q1100% · $6.155MUnavailableUnavailableUnavailableUnavailable100% · $6.155M
FY 2012 Q2100% · $15.543MUnavailableUnavailableUnavailableUnavailable100% · $15.543M
FY 2012 Q3100% · $21.396MUnavailableUnavailableUnavailable0% · $0M100% · $21.396M
FY 2012 Q4100% · $28.046MUnavailableUnavailableUnavailableUnavailable100% · $28.046M
FY 2013 Q1100% · $16.607MUnavailableUnavailableUnavailableUnavailable100% · $16.607M
FY 2013 Q2100% · $1.801MUnavailableUnavailableUnavailableUnavailable100% · $1.801M
FY 2013 Q3100% · $18.514MUnavailableUnavailableUnavailable0% · $0M100% · $18.514M
FY 2013 Q4100% · $14.471MUnavailableUnavailableUnavailableUnavailable100% · $14.471M
FY 2014 Q1100% · $15.526MUnavailableUnavailableUnavailableUnavailable100% · $15.526M
FY 2014 Q2100% · $11.701MUnavailableUnavailableUnavailableUnavailable100% · $11.701M
FY 2014 Q3100% · $9.298MUnavailableUnavailableUnavailable0% · $0M100% · $9.298M
FY 2014 Q4100% · $14.676MUnavailableUnavailableUnavailableUnavailable100% · $14.676M
FY 2015 Q1100% · $10.558MUnavailableUnavailableUnavailableUnavailable100% · $10.558M
FY 2015 Q2100% · $13.42MUnavailableUnavailableUnavailableUnavailable100% · $13.42M
FY 2015 Q3100% · $8.797MUnavailableUnavailableUnavailableUnavailable100% · $8.797M
FY 2015 Q4100% · $12.527MUnavailableUnavailableUnavailableUnavailable100% · $12.527M
FY 2016 Q1100% · $11.974MUnavailableUnavailableUnavailableUnavailable100% · $11.974M
FY 2016 Q2100% · $15.918MUnavailableUnavailableUnavailableUnavailable100% · $15.918M
FY 2016 Q3100% · $13.883MUnavailableUnavailableUnavailableUnavailable100% · $13.883M
FY 2016 Q4100% · $14.788MUnavailableUnavailableUnavailableUnavailable100% · $14.788M
FY 2017 Q1100% · $11.159MUnavailable0% · $0MUnavailableUnavailable100% · $11.159M
FY 2017 Q2100% · $17.707MUnavailable0% · $0MUnavailableUnavailable100% · $17.707M
FY 2017 Q3100% · $27.951MUnavailable0% · $0MUnavailableUnavailable100% · $27.951M
FY 2017 Q4100% · $42.604MUnavailable0% · $0MUnavailableUnavailable100% · $42.604M
FY 2018 Q174.54% · $29.279MUnavailable25.46% · $10MUnavailableUnavailable100% · $39.279M
FY 2018 Q221.99% · $29.612MUnavailable78.01% · $105.033MUnavailableUnavailable100% · $134.645M
FY 2018 Q318.52% · $20.912MUnavailable81.48% · $92.005MUnavailableUnavailable100% · $112.917M
FY 2018 Q49.9% · $15.721M0% · $0M90.1% · $143.005MUnavailableUnavailable100% · $158.726M
FY 2019 Q115.3% · $18.041MUnavailable84.7% · $99.839MUnavailableUnavailable100% · $117.88M
FY 2019 Q222.6% · $16.358MUnavailable77.4% · $56.01MUnavailableUnavailable100% · $72.368M
FY 2019 Q399.57% · $24.291MUnavailable0.43% · $0.104MUnavailableUnavailable100% · $24.395M
FY 2019 Q41.74% · $16.761M94.5% · $908.388M3.75% · $36.062MUnavailableUnavailable100% · $961.211M
FY 2020 Q16.09% · $19.45MUnavailable93.91% · $300.026MUnavailableUnavailable100% · $319.476M
FY 2020 Q2100% · $17.864MUnavailable0% · $0MUnavailableUnavailable100% · $17.864M
FY 2020 Q361.81% · $174.795MUnavailable38.19% · $108.007MUnavailableUnavailable100% · $282.802M
FY 2020 Q426.67% · $47.689M0% · $0M73.33% · $131.103MUnavailableUnavailable100% · $178.792M
FY 2021 Q114.3% · $70.926MUnavailable85.7% · $424.952MUnavailableUnavailable100% · $495.878M
FY 2021 Q2100% · $49.837MUnavailable0% · $0MUnavailableUnavailable100% · $49.837M
FY 2021 Q37.67% · $52.522MUnavailable92.33% · $632.273MUnavailableUnavailable100% · $684.795M
FY 2021 Q414.36% · $61.715M0% · $0M85.64% · $368.175MUnavailableUnavailable100% · $429.89M
FY 2022 Q1100% · $63.6MUnavailable0% · $0MUnavailableUnavailable100% · $63.6M
FY 2022 Q2100% · $53.3MUnavailable0% · $0MUnavailableUnavailable100% · $53.3M
FY 2022 Q3100% · $54.2MUnavailable0% · $0MUnavailableUnavailable100% · $54.2M
FY 2022 Q4100% · $33.6M0% · $0M0% · $0MUnavailableUnavailable100% · $33.6M
FY 2023 Q124.07% · $42.1MUnavailable75.93% · $132.8MUnavailableUnavailable100% · $174.9M
FY 2023 Q267.8% · $59.6MUnavailable32.2% · $28.3MUnavailableUnavailable100% · $87.9M
FY 2023 Q325.76% · $40.6MUnavailable74.24% · $117MUnavailableUnavailable100% · $157.6M
FY 2023 Q427.99% · $58.1M0% · $0M72.01% · $149.5MUnavailableUnavailable100% · $207.6M
FY 2024 Q134.27% · $68.4MUnavailable65.73% · $131.2MUnavailableUnavailable100% · $199.6M
FY 2024 Q217.72% · $69MUnavailable82.28% · $320.3MUnavailableUnavailable100% · $389.3M
FY 2024 Q318.03% · $67.7MUnavailable81.97% · $307.7MUnavailableUnavailable100% · $375.4M
FY 2024 Q418.14% · $92.6MUnavailable81.86% · $417.9MUnavailableUnavailable100% · $510.5M
FY 2025 Q18.72% · $40.7MUnavailable91.28% · $426.1MUnavailableUnavailable100% · $466.8M
FY 2025 Q227.11% · $145.7MUnavailable72.89% · $391.8MUnavailableUnavailable100% · $537.5M
FY 2025 Q38.68% · $101.8MUnavailable91.32% · $1,071.1MUnavailableUnavailable100% · $1,172.9M
FY 2025 Q453.78% · $149.4MUnavailable46.22% · $128.4MUnavailableUnavailable100% · $277.8M
FY 2026 Q128.36% · $133.4MUnavailable71.64% · $336.9MUnavailableUnavailable100% · $470.3M
FY 2026 Q219.29% · $112.2MUnavailable80.71% · $469.5MUnavailableUnavailable100% · $581.7M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Vertex Pharmaceuticals.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources